<DOC>
	<DOCNO>NCT01928030</DOCNO>
	<brief_summary>This phase 1-2 trial study side effect best dose recombinant human hyaluronidase see well work treat lymphedema patient cancer . Recombinant human hyaluronidase ( r-hu-hyaluronidase , rHuPH20 ) may reduce limb edema size patient lymphedema .</brief_summary>
	<brief_title>Recombinant Human Hyaluronidase Treating Lymphedema Patients With Cancer</brief_title>
	<detailed_description>This phase 1 , dose-escalation study follow phase 2 study . Phase 1 : rHuPH20 subcutaneously ( SC ) day 1 , 3 , 5 , 7 Phase 2 : rHuPH20 SC day 1 21</detailed_description>
	<mesh_term>Lymphedema</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Unilateral upper limb secondary lymphedema Must ability understand willingness sign write informed consent document Must agree blood serum assessment include , complete blood count ( CBC ) differential ; comprehensive metabolic panel serum osmolality every sanctioned evaluation ; additionally physician may require cardiac evaluation echocardiogram , electrocardiogram , brain natriuretic peptide urinalysis deem appropriate Must consent multibiofrequency impedance analysis ( MFBIA ) ; detail cover consent Willing sign consent skin biopsy phlebotomy Women child bear potential must document negative pregnancy test within 2 week prior day 1 treatment agree use nonhormonal form birth control duration trial therapy Pregnant actively breastfeed Bilateral upper extremity edema Bilateral manipulation axilla within last 24 month Active infection Receiving concomitant treatment upper extremity lymphedema , receive treatment within last 14 day Known allergic hypersensitivity reaction rHUPH20 hyaluronidase extract Receiving concomitant diuretic dihydropyridine class calcium channel blocker ; alternative medication available , patient become eligible 3 halflives drug discontinue patient remain medically stable Grade 2 great hypoalbuminemia , serum sodium great 150meq/L , serum osmolality great 300mOsm/kg blood urea nitrate/serum creatinine ratio great 25 , within 7 day screen Unable unwilling self/home administer subcutaneous experimental drug ; study nurse physician train individual proper administration technique Unwilling incapable maintain detailed log number injection , date , time site administration Active malignancy ; undergo active treatment malignancy adjuvant set eligible ; treatment include chemotherapy , target therapy antihormonal therapy At least 4 week remove surgery radiation affect arm Primary lymphedema ; edema explain systemic congenital illness , patient eligible study Must concurrent condition investigator 's opinion make inappropriate patient participate trial would jeopardize compliance protocol Must receive investigational agent within 30 day prior commence study treatment Active thrombophlebitis Pulmonary edema , congestive heart failure pulmonary embolus</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>